Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ADCT – Adc Therapeutics SA

ADC Therapeutics SA
ADCT
$3.18
Name : ADC Therapeutics SA
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $357,746,816.00
EPSttm : -1.55
finviz dynamic chart for ADCT
ADC Therapeutics SA
$3.18
2.58%
$0.08

Float Short %

6.44

Margin Of Safety %

Put/Call OI Ratio

1.17

EPS Next Q Diff

0.16

EPS Last/This Y

0.09

EPS This/Next Y

0.23

Price

3.18

Target Price

8.25

Analyst Recom

1

Performance Q

42.6

Relative Volume

1.45

Beta

1.99

Ticker: ADCT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ADCT3.280.900.001870
2025-07-28ADCT3.10.900.001877
2025-07-29ADCT2.90.900.001878
2025-07-30ADCT2.950.890.001880
2025-07-31ADCT2.760.890.001882
2025-08-01ADCT2.70.90999.991876
2025-08-04ADCT2.720.910.001886
2025-08-05ADCT2.770.910.001886
2025-08-06ADCT2.630.910.001885
2025-08-07ADCT2.640.90999.991890
2025-08-08ADCT2.690.900.001890
2025-08-11ADCT2.70.900.001896
2025-08-12ADCT2.920.890.001900
2025-08-13ADCT3.070.860.001945
2025-08-14ADCT3.170.780.062047
2025-08-15ADCT3.130.780.002038
2025-08-18ADCT3.231.180.001635
2025-08-19ADCT3.121.170.001642
2025-08-20ADCT3.111.170.001642
2025-08-21ADCT3.111.170.001642
2025-08-22ADCT3.181.170.001641
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ADCT3.28- - 0.00
2025-07-28ADCT3.10- - 0.00
2025-07-29ADCT2.89- - 0.00
2025-07-30ADCT2.94- - 0.00
2025-07-31ADCT2.77- - 0.00
2025-08-01ADCT2.69- - 0.00
2025-08-04ADCT2.73- - 0.00
2025-08-05ADCT2.76- - 0.00
2025-08-06ADCT2.64- - 0.00
2025-08-07ADCT2.64- - 0.00
2025-08-08ADCT2.68- - 0.00
2025-08-11ADCT2.69- - 0.00
2025-08-12ADCT2.92- - 0.00
2025-08-13ADCT3.09- - 0.00
2025-08-14ADCT3.18- - 0.00
2025-08-15ADCT3.12- - 0.00
2025-08-18ADCT3.24- - 0.00
2025-08-19ADCT3.11- - 0.00
2025-08-20ADCT3.10- - 0.00
2025-08-21ADCT3.10- - 0.00
2025-08-22ADCT3.18- - -1.53
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ADCT0.0033.537.04
2025-07-28ADCT0.0026.757.04
2025-07-29ADCT0.0026.757.04
2025-07-30ADCT0.0026.757.04
2025-07-31ADCT0.0026.757.04
2025-08-01ADCT0.0026.757.04
2025-08-04ADCT0.0027.167.04
2025-08-05ADCT0.0027.167.04
2025-08-06ADCT0.0027.167.04
2025-08-07ADCT0.0027.167.04
2025-08-08ADCT0.0027.167.04
2025-08-11ADCT0.0027.207.04
2025-08-12ADCT0.0027.207.31
2025-08-13ADCT0.0027.207.31
2025-08-14ADCT0.0027.207.31
2025-08-15ADCT0.0027.206.45
2025-08-18ADCT0.0021.446.45
2025-08-19ADCT0.0021.446.44
2025-08-20ADCT0.0021.446.44
2025-08-21ADCT0.0021.446.44
2025-08-22ADCT0.0021.446.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.34

Insider Transactions

Institutional Transactions

21.44

Beta

1.99

Average Sales Estimate Current Quarter

18

Average Sales Estimate Next Quarter

18

Fair Value

Quality Score

71

Growth Score

27

Sentiment Score

50

Actual DrawDown %

93.2

Max Drawdown 5-Year %

-99

Target Price

8.25

P/E

Forward P/E

PEG

P/S

4.63

P/B

P/Free Cash Flow

EPS

-1.57

Average EPS Est. Cur. Y​

-1.53

EPS Next Y. (Est.)

-1.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-220

Relative Volume

1.45

Return on Equity vs Sector %

60.6

Return on Equity vs Industry %

73.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

ADC Therapeutics SA
Sector: Healthcare
Industry: Biotechnology
Employees: 263
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today
news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025
marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance
stock history ADCT – Adc Therapeutics SA invest stock market
stock prices ADCT premarket after hours
ticker ADCT fair value insiders trading